Drug intelligence / Profile preview

BMS-986481

Development stage: Unknown
Lead developer: NewCo

Overview

BMS-986481 is a **Phase 1-ready biologic drug** that targets the **IL18 pathway**. It is being developed for **autoimmune diseases**, specifically as part of a portfolio focusing on new immunology mechanisms that may address significant unmet needs in the treatment of autoimmunity. Originally developed by Bristol Myers Squibb, as of July 2025 the asset has been transferred to a newly formed, independent biopharmaceutical company dedicated to immunology and backed by Bain Capital. The drug is designed to modulate the immune response by affecting interleukin-18 (IL18), a cytokine involved in inflammatory and autoimmune signaling[1][2][3].

Targets

IL18 (Interleukin-18)

Beyond the preview

Go deeper on BMS-986481.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMS-986481.

Explore the full profile